ArticleBreast cancer research and treatment2026
Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionInterstitial lung disease (ILD) is a serious side effect of certain mBC treatments, but our understanding of its prevalence outside of clinical trials and treatment-specific studies is limited. We sought to characterize the incidence of ILD among a large, population-based cohort of adults with mBC in the United States.
methodsWe included females and males aged 66 + years who were diagnosed with Stage IV breast cancer (as their first cancer) between January 1, 2002-December 31, 2017, using the SEER-Medicare linked. Our primary outcome was an incident ILD diagnosis after their mBC diagnosis, which was operationalized as a binary outcome. We examined demographic and clinical factors associated with incident ILD using logistic regression models.
resultsAmong the 14,343 patients with mBC and no evidence of ILD at baseline, the median age at diagnosis was 76 (IQR 70, 82) years and 98% were female. Overall, 1,806 (12.6%) had an ILD diagnosis after mBC diagnosis. There was no significant difference in proportion of patients who received a pharmacologic treatment that carries the potential risk of ILD between patients who received an ILD diagnosis and those who did not (14% vs. 12%).
conclusionsILD is prevalent in 12.6% of adults with mBC, yet oncology guidelines for monitoring for this intrusive and potentially fatal complication are sparse and non-specific. Patient education raising awareness of ILD symptoms and engaging primary care and pulmonary medicine in may improve patient outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.